Gepotidacin – Oral Products
| Minimum Inhibitory Concentrations (mcg/mL) |
Disk Diffusion (zone diameter in mm) |
|||||
|---|---|---|---|---|---|---|
| Pathogen | S | I | R | S | I | R |
| Enterobacteralesa | ≤ 16 | 32 | ≥ 64 | ≥ 12 | 8-11 | ≤ 7 |
| Staphylococcus saprophyticus | ≤0.25 | - | - | ≥ 23 | - | - |
| Enterococcus faecalis | ≤4 | - | - | ≥ 14 | ||
S = susceptible; I = intermediate; R = resistant
a Clinical efficacy was shown for Escherichia coli, Klebsiella pneumoniae, and Citrobacter freundii complex.
Distribution channels: Healthcare & Pharmaceuticals Industry
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release